#USA #Dallas #GC Biopharma #IVIG #ALYGLO

GC Biopharma to Host Symposium at 2025 IgNS Annual Meeting

GC Biopharma USA, Inc., a prominent name in the field of plasma-derived products, has announced its participation in the upcoming 2025 Immunoglobulin National Society (IgNS) Annual Meeting scheduled for October 16-19 in Dallas, Texas. The company will not only sponsor a symposium but also present two scientific posters, highlighting significant advances in intravenous immunoglobulin (IVIG) treatment and manufacturing processes. This event promises to provide a unique platform to discuss clinical insights and patient perspectives concerning primary immunodeficiency (PI).

Commitment to Patient-Centric Approaches

Stacey Ness, PharmD, an integral member of GC Biopharma’s Medical Affairs team, emphasized their dedication to enhancing education around IVIG therapies. She stated, "These sessions underscore GC Biopharma's commitment to advancing education in IVIG therapies by sharing important data and varied perspectives that support informed multidisciplinary patient-centered decision making." With this pledge, the symposium aims to foster a discussion that marries patient experiences with clinical choices made by healthcare providers.

Symposium Details

The symposium, titled “From Patient Voices to Clinical Choices: Bridging Perspectives in Primary Immunodeficiency,” will occur on Saturday, October 18, from 7:30 AM to 9:00 AM CT. Esteemed speakers include:

• - Antoine Azar, MD, FAAAAI, Associate Professor of Medicine at Johns Hopkins Bayview Medical Center
• - Megan Ryan, a passionate Patient Advocate
• - Stacey Ness, PharmD, Medical Science Liaison at GC Biopharma

The symposium will explore how patient narratives can shape clinical practices, illustrating an essential connection between experiences and treatment protocols.

Scientific Posters: Focus Areas

In addition to the informative symposium, GC Biopharma will showcase critical scientific work through two poster presentations scheduled for October 18 from 5:00 PM to 6:30 PM CT. The presentations will be led by Dr. Ness and Suzanne Strasters, MSN, FNP-C, Head of Clinical Education at GC Biopharma. The focus areas for the posters include:
1. Manufacturing Process Optimization of Immune Globulin Intravenous-stwk 10% Liquid for Removal of Plasma-Derived Impurities
2. Investigating the Viscosity of Commercial IG Products
These presentations will delve into the advancements in manufacturing processes, showcasing how innovation is critical for improving IVIG therapy efficacy and safety.

The Importance of Innovation in IVIG

With over 50 years of experience in plasma protein manufacturing, GC Biopharma is at the forefront of setting new standards in the field. Its renowned product, ALYGLO® (immune globulin intravenous, human-stwk, 10% liquid), is a glycine-stabilized formulation crafted from pooled human plasma and manufactured to minimize virus transmission risks through rigorous processes like solvent/detergent treatment and 20 nm nanofiltration. A noteworthy inclusion in ALYGLO's manufacturing is the G-XI™ Technology, a novel cation exchange chromatography method aimed at removing coagulation factor XIa to undetectable levels. This advancement speaks to the ongoing commitment to enhance patient safety and therapeutic effectiveness.

About ALYGLO®

ALYGLO® is indicated for treating primary humoral immunodeficiency in adults over 17, including conditions like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. It bears a promise to those suffering from PI, providing essential support through its designed treatments. The detailed safety profile outlines potential risks, including thrombosis and renal dysfunction while highlighting that ALYGLO does not contain sucrose, making it safer for at-risk patients. Its administration should be handled cautiously, adhering to recommended protocols for monitoring, while also being aware of its contraindications.

Conclusion

As the 2025 IgNS Annual Meeting approaches, GC Biopharma's strategic engagements—the symposium and poster presentations—underscore the company’s commitment to advancing the field of immunotherapy and enhancing patient outcomes. Insightful discussions and innovative research showcased at this event will be pivotal for steering the future of IVIG therapies and improving lives afflicted by immunodeficiencies.

For more information, visit Alyglo.com to learn more about their products and upcoming initiatives.